



When does proton pump inhibitor treatment become long term? A scoping review

Peter Fentz Haastrup ¹, Dorte Ejg Jarbøl,¹ Wade Thompson,¹ Jane Møller Hansen,² Jens Søndergaard,¹ Sanne Rasmussen¹

To cite: Haastrup PF, Jarbøl DE, Thompson W, *et al.* When does proton pump inhibitor treatment become long term? A scoping review. *BMJ Open Gastro* 2021;**8**:e000563. doi:10.1136/bmjgast-2020-000563

Received 2 November 2020

Revised 18 January 2021

Accepted 28 January 2021

ABSTRACT

Objective Proton pump inhibitor (PPI) use has risen substantially, primarily driven by ongoing use over months to years. However, there is no consensus on how to define long-term PPI use. Our objectives were to review and compare definitions of long-term PPI use in existing literature and describe the rationale for each definition.

Moreover, we aimed to suggest generally applicable definitions for research and clinical use.

Design The databases PubMed and Cochrane Library were searched for publications concerning long-term use of PPIs and ClinicalTrials.gov was searched for registered studies. Two reviewers independently screened the titles, abstracts, and full texts in two series and subsequently extracted data.

Results A total of 742 studies were identified, and 59 met the eligibility criteria. In addition, two ongoing studies were identified. The definition of long-term PPI use varied from >2 weeks to >7 years. The most common definition was ≥1 year or ≥6 months. A total of 12/61 (20%) of the studies rationalised their definition.

Conclusion The definitions of long-term PPI treatment varied substantially between studies and were seldom rationalised.

In a clinical context, use of PPI for more than 8 weeks could be a reasonable definition of long-term use in patients with reflux symptoms and more than 4 weeks in patients with dyspepsia or peptic ulcer. For research purposes, 6 months could be a possible definition in pharmacoepidemiological studies, whereas studies of adverse effects may require a tailored definition depending on the necessary exposure time. We recommend to always rationalise the choice of definition.

INTRODUCTION

Proton pump inhibitors (PPIs) are commonly used drugs worldwide. In Denmark, PPI prescriptions are redeemed by more than 10% of the population each year.¹ Incident and prevalent PPI use are rising, the latter driven primarily by ongoing use over months to years.^{2,3} This has raised questions about whether continuous PPI therapy is actually needed in many patients. Around 40% of PPI users may be treated without an ongoing

registered indication⁴ and concerns have been raised about possible adverse effects, specifically related to use of PPIs over months to years.⁵ Only 4–8 weeks of treatment with PPIs can cause rebound acid hypersecretion and acid-related symptoms in previously asymptomatic individuals,^{6,7} potentially contributing to continued use of PPIs.

Trends in PPI use have been intensely investigated in recent years, with studies consistently referring to long-term PPI use. However, there is no consensus on how to define long-term PPI use⁸ and the definitions of long-term use vary between studies. Substantial discrepancies in definitions of long-term use make it difficult to draw firm overall conclusions about the prevalence and impact of extended continuous PPI therapy and about discontinuation of long-term PPI therapy.

An appropriate uniform definition of long-term use of PPIs is relevant in a clinical context. Position statements or guidelines have provided comprehensive and rational clinical advice concerning long-term use but have not provided a clear definition of what long-term use is.^{9,10} This makes it challenging in clinical practice to determine whether and when a patient is considered a long-term user and to decide when deprescribing can be discussed.

Therefore, the objectives of this study are to review and compare definitions of long-term PPI use which have been used in the literature and explore the rationale for each definition. Furthermore, we aim to suggest a generally applicable definition of long-term use of PPIs for research and clinical use.

MATERIALS AND METHODS

To fulfil our aim of mapping the literature with a clear definition of long-term PPI use and clarifying the definition of long term,



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark

²Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark

Correspondence to

Dr Peter Fentz Haastrup; phaastrup@health.sdu.dk

we chose a scoping review methodology.¹¹ Guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Checklist for scoping reviews,¹² we searched the databases PubMed and Cochrane Library for publications concerning long-term use of PPIs. The final PubMed and Cochrane searches were conducted in January 2019. The literature searches were assisted by a research librarian with expertise in medical literature databases. The search was conducted using the search terms “long-term AND proton pump inhibitor” using the title/abstract option in the search builder.

We also searched ClinicalTrials.gov in February 2019 for registered ongoing studies using the above-mentioned search terms.

STUDY SELECTION

Two reviewers (PFH and SR) manually screened the titles, abstracts, and full texts independently in two series.

In the screening of titles and abstracts, studies were excluded by the following criteria: (1) articles published before 2003, (2) articles not written in English or a Scandinavian language, (3) case reports, (4) animal studies, (5) use of PPI for less than 2 weeks.

During the assessment of full texts, we further excluded studies without a timeframe for long-term use. Only studies with a concrete definition of long-term use were included, hence studies using definitions perceived as indirect or vague, leaving the interpretation to the authors, were excluded. Any uncertainties and disagreements throughout the study selection process were discussed and resolved by consensus among PFH and SR.

Figure 1 illustrates the study selection.

DATA EXTRACTION

Data were extracted independently by two reviewers (PFH and SR) with respect to year, country, setting, study




Figure 1 Flowchart of the study selection process. GI, gastrointestinal; PPIs, proton pump inhibitors.

design, aim, definition of long-term use and rationale for choice of definition. Any discrepancies, disagreements or uncertainties were discussed between SR and PFH and agreement was established.

RESULTS

The literature search identified a total of 742 studies in PubMed and Cochrane Library, of which 59 met the final eligibility criteria. By searching ClinicalTrials.gov we identified two ongoing studies, resulting in a total of 61 studies.

The selected studies concerned various aspects of long-term PPI use: adverse effects (n=35), treatment effects (n=13), pharmacoepidemiological studies (n=5) and discontinuation or dosage reduction (n=8). Table 1 summarises the characteristics of the included studies, which contained 28 different definitions of long-term use.

The threshold for defining long-term PPI use varied from >2 weeks to >7 years of PPI use. The most common definition was ≥ 1 year (10 studies) or ≥ 6 months (10 studies). Nine studies defined long-term use as ≥ 8 weeks. A total of 10 studies used number of prescriptions, number of tablets or defined daily dose (DDD) in their definition. However, there was substantial variability in DDD/unit of time to define long-term use. Four studies used repeat prescriptions to define long-term use.

A total of 12 out of 61 studies (20 %) stated a specific explanation for their choice of long-term definition. Most studies rationalised their choice by referring to previous studies, guidelines or policy papers.

The definition of long-term use also varied within publications by the same author. In a study by Lundell *et al* from 2009,¹³ long-term treatment was defined as >8 weeks when examining treatment failure in the follow-up of treatment effect. Six years later, Lundell *et al* defined long-term use as >3 years when studying the effects of long-term PPI use on serum gastrin levels and gastric histology.¹⁴

DISCUSSION

Main findings

In our review we were able to identify 61 studies on different aspects related to long-term use of PPIs. The definitions of long-term use varied substantially between studies and consensus in the literature on how to define long-term use of PPIs is lacking. One in five studies stated an explanation for their choice of definition.

Comparison with previous literature

To our knowledge this is the first study systematically assessing the different definitions used in studies of long-term use of PPIs. In a review from 2005, Raghunath *et al*⁸ mention that there is no consensus on how to define long-term use and state the definitions used in some previous studies without attempting to establish a consensus-based definition. Additionally, a substantial amount of studies

have emerged since 2005 and a new evaluation was required.

Implications

The substantial variability in definitions of long-term use makes it challenging to compare studies in this area. For example, it is difficult to compare the range, burden and magnitude of extended continuous PPI therapy when definitions of 'long-term' use vary widely. More uniform definitions could improve these aspects and allow for more reliable conclusions to be drawn across available studies.

In a clinical context, several guidelines on PPI prescribing exist, but definitions of long-term use are often lacking. An appropriate time to discuss ongoing use may be after an initial course of PPI is finished (eg, at 2–4 weeks for uninvestigated dyspepsia) to avoid ongoing use without indication. For several studies of patients with non-erosive reflux disease/gastro-oesophageal reflux disease identified in this review, long-term use was defined as using >4 or >8 weeks.^{15–17} This may reflect the fact that efficacy trials demonstrate healing of oesophagitis with 4–8 weeks of PPI, which is also reflected in guideline recommendations.¹⁸

Once the recommended initial evidence-based course is completed and patients continue PPI treatment after 2–4/8 weeks (depending on whether the indication was dyspepsia, peptic ulcer or reflux), they could be considered long-term users. At this point, some patients may no longer require continuous PPI (from an efficacy/indication standpoint) and the indication for ongoing therapy could be discussed. However, it is unclear whether this currently happens widely in practice. Therefore, we suggest discussing appropriate PPI therapy with the patient after 2–4 weeks if the indication is uninvestigated dyspepsia and after 4–8 weeks if the indication is reflux symptoms where long-term treatment often is necessary.

From a research perspective, the optimal definition of long-term use may depend on the aim of the study. Long-term use most likely needs to be defined differently if the aim is to study side effects occurring after years of continuous use versus studying pharmacoepidemiological aspects of PPI use such as drug utilisation or characteristics of patients using PPIs or of doctors prescribing PPIs. As an example, the inconsistency in the definitions used by Lundell *et al* is probably due to a deliberate selection of definitions expedient to the given research aim.

The most appropriate definition may also depend on whether the aim is to study aspects of only continuous daily use of PPI or the aim is to include intermittent use of PPIs as well. It has been demonstrated that many patients use PPI sporadically and only a minority are taking PPIs continuously.¹⁹ When choosing a definition of long-term use, it is important to keep in mind that restricting the definition to continuous daily use might exclude the many PPI users from the study population.

Table 1 Overview of the included studies**Definition based on time (n=51)****Studies of side effects related to long-term PPI use (n=29)**

Author, year	Country	Setting	Study design	Aim	Definition of long-term use	Rationale
Hastrup <i>et al</i> , 2018 ⁵	Denmark	N/A	Review	Overview of side effects of long-term PPI use	>2 weeks	Earlier studies showing no important side effects if used ≤2 weeks
Revaiah <i>et al</i> , 2018 ²⁰	India	Secondary sector	Single-centre, cross-sectional	Risk of small bacterial overgrowth in PPI users	>3 months	No
Torvinen-Kiiskinen <i>et al</i> , 2018 ²¹	Finland	Primary sector	Case-control	Risk of hip fractures among community-dwelling residents with Alzheimer's	≥1 year	No
Biyik <i>et al</i> , 2017 ²²	Turkey	Outpatient gastroenterology clinic	Cohort study	Risk of hypomagnesaemia in PPI users	≥6 months	No
Takahari <i>et al</i> , 2017 ²³	Japan	Secondary sector	Cross-sectional	Frequency of gastric cobblestone-like lesions in PPI users undergoing endoscopy	≥6 months	No
Lochhead <i>et al</i> , 2017 ²⁴	USA	Nurses' health study	Cross-sectional	Association between PPI use and cognitive function	≥2 years	No
Kearns <i>et al</i> , 2017 ²⁵	UK	Primary sector	Case-control	Association between PPI use and pancreatic cancer	>2 years	Avoiding reverse causation
Targownik <i>et al</i> , 2017 ²⁶	Canada	General population	Cross-sectional	Association between PPI use and bone structure	≥5 years	No
Bahtiri <i>et al</i> , 2017 ²⁷	Turkey	General population	Cohort	Risk of hypomagnesaemia	12 months	No
Huang <i>et al</i> , 2016 ²⁸	Taiwan	General population	Cohort	Association between PPI use and risk of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis	>180 days	No
Takeda <i>et al</i> , 2015 ²⁹	Japan	Outpatients	Cross-sectional	Prevalence of hypomagnesaemia	>1 year	No
Lundell <i>et al</i> , 2015 ¹⁴	N/A	Systematic review	Systematic review	Effects of PPI on serum gastrin levels and gastric histology	>48 months	FDA requesting 3-year safety data from manufacturers
Song <i>et al</i> , 2014 ³⁰	Cochrane review	N/A	Systematic review	Risk of gastric pre-malignant lesions in PPI users	≥6 months	No
Lewis <i>et al</i> , 2014 ³¹	Australia	General population	Cohort	PPIs and risk of falls and fractures in elderly women	≥1 year	No
Helgadóttir, 2014 ³²	Iceland	Secondary sector	Cross-sectional	Serum gastrin levels in PPI users	≥2 years	No
Bektas <i>et al</i> , 2012 ³³	Turkey	Secondary sector	Cross-sectional	ECL hyperplasia in PPI users	≥6 months	No

Continued

Table 1 Continued

Definition based on time (n=51)
Studies of side effects related to long-term PPI use (n=29)

Author, year	Country	Setting	Study design	Aim	Definition of long-term use	Rationale
Pregun <i>et al</i> , 2011 ³⁴	Hungary	Secondary sector	Cohort	Effect of PPI on serum chromogranin-A and gastrin levels	>6 months	No
Sarzynski <i>et al</i> , 2011 ³⁵	USA	Primary sector	Retrospective cohort	Association between PPI use and iron-deficiency anaemia	>1 year	No
Fujimoto and Hongo, 2011 ³⁶	Japan	Multicentre	Cohort	Efficacy and safety of 104 weeks treatment with rabeprazole	104 weeks	No
Lombardo <i>et al</i> , 2010 ³⁷	Italy	Secondary sector	Cohort	Incidence of small intestinal bacterial overgrowth among PPI users	>2 months	No
Yoshikawa <i>et al</i> , 2009 ³⁸	Japan	Secondary sector	Case-control	Body mass index changes during PPI therapy in patients with GORD	>10 months	No
Ally <i>et al</i> , 2009 ³⁹	USA	Outpatient clinic	Retrospective	Risk of fundic gastric polyps in PPI users	>48 months	No
Van Soest <i>et al</i> , 2008 ⁴⁰	The Netherlands	General practice	Case-control	Risk of colorectal cancer among PPI users	>365 days within 5 years	No
Hashimoto <i>et al</i> , 2007 ⁴¹	Japan	Secondary sector	Clinical trial	PPI-induced tolerance to histamine-2-receptor antagonists	>4 weeks	No
Yang <i>et al</i> , 2007 ⁴²	UK	General practice	Case-control	Risk of colorectal cancer among PPI users	≥5 years cumulative use	The definition is argued to be able to demonstrate an accelerative effect on the transformation from adenomas to carcinomas
Robertson <i>et al</i> , 2007 ⁴³	Denmark	Population based	Case-control	Risk of colorectal cancer among PPI users	>7 years	The definition is argued to be able to demonstrate an accelerative effect on the transformation from adenomas to carcinomas
Jalving <i>et al</i> , 2006 ⁴⁴	The Netherlands	Secondary sector	Cross-sectional	Risk of fundic gastric polyps in PPI users	≥1 years	No
Hirtz <i>et al</i> , 2005 ⁴⁵	Hungary	Secondary sector	Clinical trial	Effect of PPI on gastric cell proliferation	6 months	No
ClinicalTrials.gov	Austria	Secondary sector	Clinical trial	Intestinal microbiota in PPI users	≥6 months	No

Continued

Table 1 Continued

Definition based on time (n=51)

Studies of side effects related to long-term PPI use (n=29)

Author, year	Country	Setting	Study design	Aim	Definition of long-term use	Rationale
Studies of treatment effects of long-term PPI use (n=13)						
Kiso <i>et al</i> , 2017 ⁴⁶	Japan	Outpatient clinic	Cross-sectional	Endoscopic findings in patients undergoing gastric screening	>8 weeks	No
Funaki <i>et al</i> , 2017 ⁴⁷	Japan	Outpatient clinic	Cross-sectional	Efficacy of PPI in patients with NERD with and without irritable bowel syndrome	>6 months	ROME III criteria for functional disorders (duration >6 months)
Hatlebakk <i>et al</i> , 2016 ⁴⁸	Europe (several countries)	Secondary sector	RCT	Comparing anti-reflux surgery with PPI treatment in patients with chronic GERD	5 years	No
Yoon <i>et al</i> , 2014 ⁴⁹	South Korea	HP-positive patients	RCT	Eradication rates with different durations of pretreatment with PPI	≥56 days	No
Poh <i>et al</i> , 2011 ¹⁷	USA	Outpatient clinic	RCT	Comparing stimulus response functions to acid in users and non-users of PPI undergoing acute stress	8 weeks	No
Labenz <i>et al</i> , 2009 ⁵⁰	Sweden	Secondary sector	RCT	Predictors of symptom resolution in patients with GERD during maintenance PPI therapy	>6 months	Maintenance phase after healed oesophagitis
Sugano <i>et al</i> , 2013 ⁵¹	Japan	Outpatient clinic	Clinical trial	Gastroprotective effect of omeprazole	1 year	No
Fujimoto and Hongo, 2010 ⁵²	Japan	Secondary sector	Cohort	Relapse of GERD during long-term PPI therapy	104 weeks	No
Kandil <i>et al</i> , 2010 ¹⁵	Egypt	Outpatient clinic	Cohort	Effect of exogenous melatonin in patients with GERD	4 and 8 weeks	No
Mason <i>et al</i> , 2008 ⁵³	UK	General practice	RCT	Effect of HP eradication in long-term users of PPI	A repeat prescription for PPI begun at least 12 months ago	Previous article by Hungin <i>et al</i> ⁵⁴
Raghunath <i>et al</i> , 2009 ⁵⁵	UK	Primary care	Cross-sectional	Symptoms in patients on long-term PPI therapy	A repeat prescription for PPI begun at least 12 months ago	Previous article by Hungin <i>et al</i> ⁵⁴
Usai <i>et al</i> , 2008 ¹⁶	Italy	Secondary sector	Cohort	Recurrence of reflux symptoms in patients with coeliac disease with NERD	>8 weeks	No

Continued

Table 1 Continued

Definition based on time (n=51)
Studies of side effects related to long-term PPI use (n=29)

Author, year	Country	Setting	Study design	Aim	Definition of long-term use	Rationale
Frazzoni <i>et al</i> , 2007 ⁵⁶	Italy	Secondary sector	Cohort	Efficacy of long-term PPI on intraoesophageal acid suppression	2 years of continuous use	No
Studies of deprescribing long-term PPI (n=6)						
Pezeszkian and Conway, 2018 ⁵⁷	USA	N/A	Review	Guidance on deprescribing PPI in older adults	>12 weeks	Approved duration of treatment
Boghossian <i>et al</i> , 2017 ⁵⁸	Cochrane review	N/A	Systematic review	Effects of deprescribing PPI in adults	≥28 days	No
Walsh <i>et al</i> , 2016 ⁵⁹	Canada	General practice	Cross-sectional	Deprescribing	≥8 weeks	Guideline recommending reassessment of PPIs after 8 weeks
Van der Velden <i>et al</i> , 2013 ⁶⁰	The Netherlands	Primary care	RCT	Deprescribing	≥1 year	No
Bjornsson <i>et al</i> , 2006 ⁶¹	Sweden	Secondary sector	Clinical trial	Discontinuation	>8 weeks	No
Krol <i>et al</i> , 2004 ⁶²	The Netherlands	General practice	RCT	Discontinuation	≥12 weeks	No
Pharmacoepidemiological studies of long-term PPI use (n=3)						
Othman <i>et al</i> , 2016 ⁶³	UK	General population	Cohort	Prevalence and pattern of PPI prescribing	≥1 year continuous use	No
Lødrup <i>et al</i> , 2014 ⁶⁴	Denmark	General population	Survey	Use of PPIs	≥120 days the past year	No
Haron <i>et al</i> , 2015 ⁶⁵	Ireland	Secondary sector	Survey	Reasons for treatment	2 years	No
Definition based on quantity of PPI (n=10)						
Studies of side effects related to long-term PPI use (n=6)						
Imfeld <i>et al</i> , 2018 ⁶⁶	UK	General population	Case-control	Risk of dementia	≥100 prescriptions	No
Shao <i>et al</i> , 2018 ⁶⁷	Taiwan	General population	Case-control	Risk of hepatocellular carcinoma	>28 DDDs	No

Continued

Table 1 Continued

Definition based on time (n=51)						
Studies of side effects related to long-term PPI use (n=29)						
Author, year	Country	Setting	Study design	Aim	Definition of long-term use	Rationale
Sieczkowska <i>et al</i> , 2016 ⁶⁸	Poland	Outpatient clinic and general practice	Cohort	Risk of small intestinal bacterial overgrowth	PPI for at least 75% of the time during the previous 3 months at a minimum dose of 20mg per day	No
Chien <i>et al</i> , 2016 ⁶⁹	Taiwan	General population	Case-control	Risk of periampullar cancer	>180 DDDs	No
Clooney <i>et al</i> , 2016 ⁷⁰	Canada	General population	Cross-sectional	Gut microbiome in long-term PPI users	>180 tablets each year in a 5-year period	No
Den Eizen <i>et al</i> , 2008 ⁷¹	The Netherlands	General population	Cross-sectional	Risk of vitamin B ₁₂ deficiency	>810 DDDs in 3 years	No
Studies of deprescribing long-term PPI (n=2)						
Reimer and Bytzer, 2010 ⁷²	Denmark	Primary care	Cross-sectional	Discontinuation in symptomatically treated patients	120 tablets of any PPI in the previous 12 months	No
Clinicaltrials.gov	USA	Primary care	Clinical trial	Evaluation of a deprescribing programme	90-day prescription within 120 days	No
Pharmacoepidemiological studies of long-term PPI use (n=2)						
Wallerstedt <i>et al</i> , 2017 ⁴	Sweden	General population	Cross-sectional	Prevalence of PPI use among residents ≥65 years	Filled prescriptions for PPI covering ≥75% of the year	No
Haastrup <i>et al</i> , 2016 ²	Denmark	General population	Cohort	Predictors of incident long-term use among first-time users	>60 DDDs within 6 months	Definition used in other studies

DDDs, defined daily doses; ECL, enterochromaffin-like; FDA, Food and Drug Administration; GERD, gastro-oesophageal reflux disease; HP, *Helicobacter pylori*; N/A, not available; NERD, non-erosive reflux disease; PPI, proton pump inhibitor; RCT, randomised controlled trial.

Therefore, it is not possible to have just one definition of long-term use that is appropriate for all research purposes and the definition used should fit the aim and context of the study. If the aim is to study drug utilisation or magnitude of long-term use, we suggest a long-term definition of 6 months as a possible definition. Most PPIs are supplied in packages of no more than 100 pills. Thus, taking PPIs daily for 6 months would require at least one renewal of the prescription. Patients initially redeeming 100 pills, but not using all of them, would not be classified as long-term users.

If the aim is to study side effects related to long-term use, the definition of long term might need to be shorter or longer than 6 months depending on the length of exposure time needed for the side effect to occur.

In conclusion, we observed substantial variability in definitions of long-term PPI treatment. The majority of definitions did not include a rationale for the choice of definition. The variety of definitions complicates the comparison of research results and raises challenges in clinical practice, such as identifying an appropriate timeframe for discussing deprescribing. We suggest that long-term use could be defined as more than 4–8 weeks of PPI use in a clinical context depending on the indication for PPI therapy. One definition does not fit all research purposes. Thus, we suggest more than 6 months of PPI use as a possible definition for long-term use in pharmacoepidemiological studies and for studies of adverse effects the definition should be tailored the exposure time needed for the side effect in question to occur. When studying long-term use of PPIs, we suggest always giving well-argued choices of definitions.

Acknowledgements We thank research medical librarian emeritus, Johan Wallin, for assistance with the literature search.

Contributors All authors contributed to the design of the study. The literature selection process and data extraction were done by PFH and SR. PFH drafted the first version of the manuscript and all authors contributed with comments and suggestions for improvement. All authors accepted the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data may be obtained from the included studies available through public databases.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Peter Fentz Hastrup <http://orcid.org/0000-0001-7265-743X>

REFERENCES

- 1 The Danish health data authority. Available: <https://medstat.dk/> [Accessed Mar 2019].
- 2 Hastrup PF, Paulsen MS, Christensen RD, *et al*. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. *Aliment Pharmacol Ther* 2016;44:78–87.
- 3 Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Use of anti-secretory medication: a population-based cohort study. *Aliment Pharmacol Ther* 2004;20:577–83.
- 4 Wallerstedt SM, Fastbom J, Linke J, *et al*. Long-Term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection—a cross-sectional population-based study. *Pharmacoepidemiol Drug Saf* 2017;26:9–16.
- 5 Hastrup PF, Thompson W, Søndergaard J, *et al*. Side effects of long-term proton pump inhibitor use: a review. *Basic Clin Pharmacol Toxicol* 2018;123:114–21.
- 6 Reimer C, Søndergaard B, Hilsted L, *et al*. Proton-Pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. *Gastroenterology* 2009;137:80–7.
- 7 Niklasson A, Lindström L, Simrén M, *et al*. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. *Am J Gastroenterol* 2010;105:1531–7.
- 8 Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. *Aliment Pharmacol Ther* 2005;22:55–63.
- 9 Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American gastroenterological association. *Gastroenterology* 2017;152:706–15.
- 10 Scarpignato C, Gatta L, Zullo A, *et al*. Effective and safe proton pump inhibitor therapy in acid-related diseases – a position paper addressing benefits and potential harms of acid suppression. *BMC Med* 2016;14:179.
- 11 Munn Z, Peters MDJ, Stern C, *et al*. Systematic review or scoping review? guidance for authors when choosing between a systematic or scoping review approach. *BMC Med Res Methodol* 2018;18:143.
- 12 Tricco AC, Lillie E, Zarin W, *et al*. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169:467–73.
- 13 Lundell L, Miettinen P, Myrvold HE, *et al*. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. *Clin Gastroenterol Hepatol* 2009;7:1292–8.
- 14 Lundell L, Vieth M, Gibson F, *et al*. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. *Aliment Pharmacol Ther* 2015;42:649–63.
- 15 Kandil TS, Mousa AA, El-Gendy AA, *et al*. The potential therapeutic effect of melatonin in gastro-esophageal reflux disease. *BMC Gastroenterol* 2010;10:7.
- 16 Usai P, Manca R, Cuomo R, *et al*. Effect of gluten-free diet on preventing recurrence of gastroesophageal reflux disease-related symptoms in adult celiac patients with nonerosive reflux disease. *J Gastroenterol Hepatol* 2008;23:1368–72.
- 17 Poh CH, Hershovici T, Gasiorowska A, *et al*. The effect of antireflux treatment on patients with gastroesophageal reflux disease undergoing a mental arithmetic stressor. *Neurogastroenterol Motil* 2011;23:e489–96.
- 18 Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013;108:308–28.
- 19 Pottegård A, Broe A, Hallas J, *et al*. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. *Therap Adv Gastroenterol* 2016;9:671–8.
- 20 Revaiah PC, Kochhar R, Rana SV, *et al*. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. *JGH Open* 2018;2:47–53.
- 21 Torvinen-Kiiskinen S, Tolppanen A-M, Koponen M, *et al*. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease—a nested case-control study. *Aliment Pharmacol Ther* 2018;47:1135–42.
- 22 Biyik M, Solak Y, Ucar R, *et al*. Hypomagnesemia among outpatient long-term proton pump inhibitor users. *Am J Ther* 2017;24:e52–5.
- 23 Takahari K, Haruma K, Ohtani H, *et al*. Proton pump inhibitor induction of gastric Cobblestone-like lesions in the stomach. *Intern Med* 2017;56:2699–703.
- 24 Lochhead P, Hagan K, Joshi AD, *et al*. Association between proton pump inhibitor use and cognitive function in women. *Gastroenterology* 2017;153:971–9.



- 25 Kearns MD, Boursi B, Yang Y-X. Proton pump inhibitors on pancreatic cancer risk and survival. *Cancer Epidemiol* 2017;46:80–4.
- 26 Targownik LE, Goertzen AL, Luo Y, et al. Long-Term proton pump inhibitor use is not associated with changes in bone strength and structure. *Am J Gastroenterol* 2017;112:95–101.
- 27 Bahtiri E, Islami H, Hoxha R, et al. Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study. *Turk J Gastroenterol* 2017;28:104–9.
- 28 Huang K-W, Kuan Y-C, Luo J-C, et al. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. *Eur J Intern Med* 2016;32:91–5.
- 29 Takeda Y, Doyama H, Tsuji K, et al. Does long-term use of proton pump inhibitors cause hypomagnesaemia in Japanese outpatients? *BMJ Open Gastroenterology* 2014;1:e000003.
- 30 Song H, Zhu J, Lu D. Long-Term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. *Cochrane Database Syst Rev* 2014;35:Cd010623.
- 31 Lewis JR, Barre D, Zhu K, et al. Long-Term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. *J Bone Miner Res* 2014;29:2489–97.
- 32 Helgadóttir H, Metz DC, Yang Y-X, et al. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. *Dig Liver Dis* 2014;46:125–30.
- 33 Bektaş M, Saraç N, Cetinkaya H, et al. Effects of *Helicobacter pylori* infection and long-term proton pump inhibitor use on enterochromaffin-like cells. *Ann Gastroenterol* 2012;25:123–7.
- 34 Pregon I, Herszényi L, Juhász M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin A level. *Digestion* 2011;84:22–8.
- 35 Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. *Dig Dis Sci* 2011;56:2349–53.
- 36 Fujimoto K, Hongo M, The Maintenance Study Group. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 Mg once daily in Japanese patients with reflux esophagitis. *Intern Med* 2011;50:179–88.
- 37 Lombardo L, Foti M, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. *Clin Gastroenterol Hepatol* 2010;8:504–8.
- 38 Yoshikawa I, Nagato M, Yamasaki M, et al. Long-Term treatment with proton pump inhibitor is associated with undesired weight gain. *World J Gastroenterol* 2009;15:4794–8.
- 39 Ally MR, Veerappan GR, Maydonovitch CL, et al. Chronic proton pump inhibitor therapy associated with increased development of fundic gland polyps. *Dig Dis Sci* 2009;54:2617–22.
- 40 van Soest EM, van Rossum LGM, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. *Am J Gastroenterol* 2008;103:966–73.
- 41 Hashimoto H, Kushikata T, Kudo M, et al. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist? *J Gastroenterol* 2007;42:275–8.
- 42 Yang Y-X, Hennessy S, Probert K, et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. *Gastroenterology* 2007;133:748–54.
- 43 Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, Case-Control study. *Gastroenterology* 2007;133:755–60.
- 44 Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. *Aliment Pharmacol Ther* 2006;24:1341–8.
- 45 Hritz I, Herszényi L, Molnar B, et al. Long-Term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression. *World J Gastroenterol* 2005;11:4721–6.
- 46 Kiso M, Ito M, Boda T, et al. Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor - a multicenter study. *Scand J Gastroenterol* 2017;52:828–32.
- 47 Funaki Y, Kaneko H, Kawamura Y, et al. Impact of comorbid irritable bowel syndrome on treatment outcome in non-erosive reflux disease on long-term proton pump inhibitor in Japan. *Digestion* 2017;96:39–45.
- 48 Hatlebakk JG, Zerbib F, Bruley des Varannes S, et al. Gastroesophageal acid reflux control 5 years after antireflux surgery, compared with long-term esomeprazole therapy. *Clin Gastroenterol Hepatol* 2016;14:678–85.
- 49 Yoon SB, Park JM, Lee J-Y, et al. Long-term pretreatment with proton pump inhibitor and *Helicobacter pylori* eradication rates. *World J Gastroenterol* 2014;20:1061–6.
- 50 Labenz J, Armstrong D, Zetterstrand S, et al. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis - results from the maintenance phase of the EXPO study. *Aliment Pharmacol Ther* 2009;29:1165–71.
- 51 Sugano K, Kinoshita Y, Miwa H, et al. Safety and efficacy of long-term esomeprazole 20mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. *BMC Gastroenterol* 2013;13:54.
- 52 Fujimoto K, Hongo M. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. *J Gastroenterol* 2010;45:1193–200.
- 53 Mason JM, Raghunath AS, Hungin APS, et al. *Helicobacter pylori* eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. *Aliment Pharmacol Ther* 2008;28:1297–303.
- 54 Hungin AP, Rubin GP, O'Flanagan H. Long-Term prescribing of proton pump inhibitors in general practice. *Br J Gen Pract* 1999;49:451–3.
- 55 Raghunath AS, Hungin APS, Mason J, et al. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. *Aliment Pharmacol Ther* 2009;29:431–9.
- 56 Frazzoni M, Manno M, De Micheli E, et al. Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors. *Dig Liver Dis* 2007;39:415–21.
- 57 Pezeshkian S, Conway SE. Proton pump inhibitor use in older adults: long-term risks and steps for deprescribing. *Consult Pharm* 2018;33:497–503.
- 58 Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. *Cochrane Database Syst Rev* 2017;3:Cd011969.
- 59 Walsh K, Kwan D, Marr P, et al. Deprescribing in a family health team: a study of chronic proton pump inhibitor use. *J Prim Health Care* 2016;8:164–71.
- 60 van der Velden AW, de Wit NJ, Quartero AO, et al. Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error. *Digestion* 2013;87:85–90.
- 61 Björnsson E, Abrahamsson H, Simren M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. *Aliment Pharmacol Ther* 2006;24:945–54.
- 62 Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. *Aliment Pharmacol Ther* 2004;19:917–22.
- 63 Othman F, Card TR, Crooks CJ. Proton pump inhibitor prescribing patterns in the UK: a primary care database study. *Pharmacoepidemiol Drug Saf* 2016;25:1079–87.
- 64 Lødrup A, Reimer C, Bytzer P. Use of antacids, alginates and proton pump inhibitors: a survey of the general Danish population using an Internet panel. *Scand J Gastroenterol* 2014;49:1044–50.
- 65 Haroon M, Yasin F, Gardezi SKM, et al. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. *JRSM Short Rep* 2013;4:2042533313497183.
- 66 Imfeld P, Bodmer M, Jick SS, et al. Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis. *Drug Safety* 2018;41:1387–96.
- 67 Shao Y-HJ, Chan T-S, Tsai K, et al. Association between proton pump inhibitors and the risk of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2018;48:460–8.
- 68 Sieczkowska A, Landowski P, Gibas A, et al. Long-Term proton pump inhibitor therapy leads to small bowel bacterial overgrowth as determined by breath hydrogen and methane excretion. *J Breath Res* 2018;12:036006.
- 69 Chien L-N, Huang Y-J, Shao Y-HJ, et al. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study. *Int J Cancer* 2016;138:1401–9.
- 70 Clooney AG, Bernstein CN, Leslie WD, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. *Aliment Pharmacol Ther* 2016;43:974–84.
- 71 den Elzen WPJ, Groeneveld Y, de Ruijter W, et al. Long-Term use of proton pump inhibitors and vitamin B12 status in elderly individuals. *Aliment Pharmacol Ther* 2008;27:491–7.
- 72 Reimer C, Bytzer P. Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. *Eur J Gastroenterol Hepatol* 2010;22:1182–8.